Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Concepts in Pharmacogenomics and Personalized Medicine
7
TABLE 1.1 (Continued)
Summary of Dual and Triple Therapy with Omeprazole and Reported H. pylori Cure Rates Based
on CYP2C19 Genotype
H. pylori Cure Rates
(Cured Patients/Total Number of Patients) Hom EMs vs.
Drug Regimen a Hom EMs b Het EMs c PMs d PMs
Regimen 10 71.8%
(28/39)
Regimen 11 69.1%
(56/81)
80.3%
(49/61)
74.4%
(93/125)
90%
(18/20)
83.7%
(36/43)
Hom EMs vs.
Het EMs
Het EMs vs.
PMs Reference
NS NS NS 8
NS NS NS 28
Note: AMOX, amoxicillin; BID, twice daily; CLAR, clarithromycin; CYP2C19, cytochrome P450 2C19; EMs, extensive metabolizers;
H. pylori, Helicobacter pylori; LANS, lansoprazole; NS, non significant; OMP, omeprazole; PMs, poor metabolizers; QD, once
daily; QID, four times daily; RABE, rabeprazole; SUC, sucralfate; TID, three times daily.
a
Regimen 1 = OMP 20 mg QD × 6 or 8 weeks and AMOX 500 mg QID × 2 weeks; Regimen 2 = OMP 20 mg BID and AMOX 500 mg
BID × 2 weeks; Regimen 3 = OMP 40 mg/day and AMOX 2000 mg/day × 1 week; Regimen 4 = OMP 40 mg/day and AMOX
2000 mg/day and SUC 4000 mg/day × 1 week; Regimen 5 = OMP 40 mg/day and AMOX 2000 mg/day and CLAR 800 mg/day ×
1 week; Regimen 6 = OMP 20 mg BID and AMOX 500 mg TID and CLAR 200 mg TID × 1 week; Regimen 7 = OMP 20 mg BID or
LANS 30 mg BID and AMOX 500 mg TID and CLAR 200 mg TID × 1 week; Regimen 8 = OMP 20 mg BID and AMOX 1000 mg
BID and CLAR 500 mg BID × 1 week; Regimen 9 = OMP 20 mg BID and AMOX 750 mg BID and CLAR 400 mg BID × 1 week;
Regimen 10 = OMP 20 mg BID and AMOX 1000 mg BID and CLAR 500 mg BID × 1 week; Regimen 11 = OMP 20 mg BID or LANS
30 mg BID or RABE 10 mg BID and AMOX 750 mg TID and CLAR 200 mg BID.
b
Homozygous EMs = CYP2C19*1/*1.
c
Heterozygous EMs = CYP2C19*1/*2, CYP2C19*1/*3.
d
PMs = CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3*3.
e
p-Value was between homozygous and heterozygous EMs vs. PMs.
f
p-Value was analyzed by chi-squared applying the linear-by-linear association model to determine if H. pylori cure rate was reduced in
the patients’ order ranked in a trend of extensive metabolizers within each treatment group.